Tadalafil For Women: Is It Safe To Use?

The key takeaway:Tadalafil may help some women, but it is not a guaranteed solution, and more research is needed.

• Tadalafil belongs to PDE5 inhibitors, aiding blood flow.
• It is sometimes called "female Viagra" in popular media.
• Tadalafil's duration of action is approximately 36 hours.
• Female users should consult healthcare providers before use.
• Tadalafil may interact with other medications like nitrates.
• Existing studies show mixed results on tadalafil’s efficacy in women.
• It may be more effective when combined with therapy.
• Not recommended for women with certain cardiovascular conditions.
• Female use of tadalafil is still experimental and investigational.

Tadalafil may be more likely to help women whose symptoms are related to blood flow issues rather than desire issues alone.

Further information

The key takeaway:Tadalafil may help some women, but it is not a guaranteed solution, and more research is needed. Tadalafil may be more likely to help women whose symptoms are related to blood flow issues rather than desire issues alone. It may be worth discussing with a doctor if: You experience physical arousal difficulty (not just low desire) You have diabetes or cardiovascular risk factors Your symptoms started after beginning certain medications It is less likely to help if: Low desire is primarily related to stress, depression, or relationship challenges Hormonal imbalances (like low estrogen or testosterone) are the primary issue If tadalafil works for you, potential benefits may include: Some women also report improved sexual confidence when physical symptoms improve. That said, it is not a cure-all. Emotional intimacy, mental health, and hormonal balance remain important components of sexual wellness.

More common

Even though tadalafil is generally safe when prescribed appropriately, it can cause side effects. Less common but more serious risks include: Nitrate medications (often prescribed for chest pain) If you have heart disease, uncontrolled high blood pressure, liver disease, or kidney disease, tadalafil may not be safe for you. This is why speaking to a doctor before trying tadalafil is essential. Women between 30 and 45 may be entering perimenopause, the transition phase before menopause. Hormone levels—especially estrogen and testosterone—can fluctuate during this time.

Canadian Brand Name

If your symptoms sound familiar, it may not just be a blood flow issue. Hormonal shifts could be playing a central role. Before jumping to conclusions, it's worth using a free AI-powered symptom checker specifically for Peri-/Post-Menopausal Symptoms to better understand whether hormonal changes might be at the root of what you're experiencing. Understanding the root cause is key before considering medications like tadalafil. Before starting tadalafil, your doctor may explore: Changing antidepressants if sexual side effects are present Helpful if emotional or relationship factors are involved Sexual dysfunction can sometimes signal underlying health conditions, including: In some cases, reduced genital blood flow may mirror reduced blood flow elsewhere in the body. It may be worth discussing with a doctor if: You experience physical arousal difficulty (not just low desire) You have diabetes or cardiovascular risk factors Your symptoms started after beginning certain medications It is less likely to help if: Low desire is primarily related to stress, depression, or relationship challenges Hormonal imbalances (like low estrogen or testosterone) are the primary issue If tadalafil works for you, potential benefits may include: Some women also report improved sexual confidence when physical symptoms improve. That said, it is not a cure-all. Emotional intimacy, mental health, and hormonal balance remain important components of sexual wellness. Even though tadalafil is generally safe when prescribed appropriately, it can cause side effects. Less common but more serious risks include: Nitrate medications (often prescribed for chest pain) If you have heart disease, uncontrolled high blood pressure, liver disease, or kidney disease, tadalafil may not be safe for you.

This is why speaking to a doctor before trying tadalafil is essential. Women between 30 and 45 may be entering perimenopause, the transition phase before menopause. Hormone levels—especially estrogen and testosterone—can fluctuate during this time. If your symptoms sound familiar, it may not just be a blood flow issue. Hormonal shifts could be playing a central role. Before jumping to conclusions, it's worth using a free AI-powered symptom checker specifically for Peri-/Post-Menopausal Symptoms to better understand whether hormonal changes might be at the root of what you're experiencing. Understanding the root cause is key before considering medications like tadalafil.

New Competition for Viagra®

In this retrospective analysis of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) randomized clinical trial, we assessed treatment response between the sexes by examining change in 6-minute walk distance (6MWD) and time to clinical worsening (TCW). We examined the effect of menopausal status on the same treatment measures. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in the PHIRST study cohort of 340 subjects (264 females, 76 males). A univariate analysis was used to assess the effect of sex on change in 6MWD and TCW. Multivariate linear regression and Cox proportional hazards models were built for 6MWD and TCW, respectively.

Corresponding author

Women were subdivided by age as a surrogate for menopausal status. The linear trend test and the log-rank test were performed on change in 6MWD and TCW by age. For tadalafil-treated patients, a significant difference in change in 6MWD by sex (mean: 48.6 m for males vs. 34.7 m for females; P = 0.01) was found, buy tadalafil but it was not significant in multivariate analysis (P = 0.08). There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement.

Erectile dysfunction

A significant sex- or age-dependent effect on TCW was not present. In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a paucity of literature investigating the effect of menopause on response to PAH treatment. Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH. Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). Before starting tadalafil, your doctor may explore: Changing antidepressants if sexual side effects are present Helpful if emotional or relationship factors are involved Sexual dysfunction can sometimes signal underlying health conditions, including: In some cases, reduced genital blood flow may mirror reduced blood flow elsewhere in the body. That's why sexual health changes shouldn't be ignored. If you're considering tadalafil, bring these questions to your appointment: Is tadalafil safe given my health history?

• Tadalafil is a phosphodiesterase type 5 inhibitor, acting on blood vessels.
• Its potential benefits for women focus on increased genital blood flow.
• Tadalafil is not approved by FDA for female sexual disorders.
• Some clinical trials report moderate improvements in women.
• It is sometimes combined with hormonal treatments.
• Psychological factors also influence female sexual satisfaction.
• Tadalafil’s effects on orgasm intensity are under research.
• Women with pre-existing health conditions should exercise caution.
• Dose adjustments may be necessary based on individual response.

Could hormones be contributing to my symptoms? Are there alternative treatments I should tadalafil 60mg uk try first?

• Tadalafil generally takes about 30-60 minutes to work in women.
• Its effects can last up to 36 hours, providing flexibility.
• It is not a standard treatment but a research tool in women.
• The drug is often compared to sildenafil in studies.
• Women should avoid heavy meals before taking tadalafil.
• Proper hydration may improve its effectiveness.
• Women with hypertension should consult a doctor before use.
• Tadalafil may cause visual disturbances in rare cases.
• Its safety profile in women continues to be studied.

What side effects should I watch for? How will we monitor whether it's working? Your doctor may recommend blood tests, a cardiovascular check, or a hormone panel before prescribing anything.

Are there other uses for this medicine?

* Basile A, Giammò A, Gangi FM, Rindone L, Iannello S, Piloni V. Pharmacological treatment of female sexual dysfunction: an update. * Cui Y, Li J, Yu Q, Chen X, Yang X, Li J. Phosphodiesterase-5 inhibitors in female sexual dysfunction: a systematic review and meta-analysis. * Worsley R, Corazza O, Al Kadhi O, Patel V.

Other Medical Problems

Female Sexual Dysfunction: A Review of the Current Literature. We tadalafil 5mg would love to help them too. We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about. Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes.

Publisher’s Note

The provision of information by physicians, medical professionals, etc. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us. Pulmonary arterial hypertension (PAH) is a female-predominant disease, but there are little data on treatment response by sex and menopausal status. Tadalafil may offer benefits for some women aged 30–45 who struggle with physical aspects of sexual arousal. It is not FDA-approved for female sexual dysfunction It does not address emotional or hormonal causes It must be prescribed and monitored by a doctor If you're noticing changes in sexual function, don't ignore them—but don't panic either. Many causes are manageable once properly identified.

What should I do in case of overdose?

That's why sexual health changes shouldn't be ignored. If you're considering tadalafil, bring these questions to your appointment: Is tadalafil safe given my health history? Could hormones be contributing to my symptoms? Are there alternative treatments I should tadalafil 60mg uk try first? What side effects should I watch for?

Research limitations and future directions

How will we monitor whether it's working? Your doctor may recommend blood tests, a cardiovascular check, or a hormone panel before prescribing anything. Tadalafil may offer benefits for some women aged 30–45 who struggle with physical aspects of sexual arousal. It is not FDA-approved for female sexual dysfunction It does not address emotional or hormonal causes It must be prescribed and monitored by a doctor If you're noticing changes in sexual function, don't ignore them—but don't panic either. Many causes are manageable once properly identified.

Drug interactions and contraindications

If you suspect hormonal shifts may be involved, take a few minutes to complete a free symptom checker for Peri-/Post-Menopausal Symptoms to gain clarity on what might be happening with your body. Most importantly, speak to a doctor about any symptoms that are persistent, worsening, or potentially serious. Sexual health is part of your overall health—and you deserve thoughtful, evidence-based care. If something feels off, trust your instincts and get medical guidance. Safety and Efficacy of Phosphodiesterase-5 Inhibitors in the Treatment of Female Sexual Dysfunction: A Systematic Review and Meta-analysis of Randomized Clinical Trials. If you suspect hormonal shifts may be involved, take a few minutes to complete a free symptom checker for Peri-/Post-Menopausal Symptoms to gain clarity on what might be happening with your body. Most importantly, speak to a doctor about any symptoms that are persistent, worsening, or potentially serious. Sexual health is part of your overall health—and you deserve thoughtful, evidence-based care.

What is tadalafil, and how does it work?

Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required. If something feels off, trust your instincts and get medical guidance. Safety and Efficacy of Phosphodiesterase-5 Inhibitors in the Treatment of Female Sexual Dysfunction: A Systematic Review and Meta-analysis of Randomized Clinical Trials. * Basile A, Giammò A, Gangi FM, Rindone L, Iannello S, Piloni V. Pharmacological treatment of female sexual dysfunction: an update. * Cui Y, Li J, Yu Q, Chen X, Yang X, Li J. Phosphodiesterase-5 inhibitors in female sexual dysfunction: a systematic review and meta-analysis.

Abstract Abstract

ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point. In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor. Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in 6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status. * Worsley R, Corazza O, Al Kadhi O, Patel V. Female Sexual Dysfunction: A Review of the Current Literature. We tadalafil 5mg would love to help them too. We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about. Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us. Pulmonary arterial hypertension (PAH) is a female-predominant disease, but there are little data on treatment response by sex and menopausal status. In this retrospective analysis of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) randomized clinical trial, we assessed treatment response between the sexes by examining change in 6-minute walk distance (6MWD) and time to clinical worsening (TCW). We examined the effect of menopausal status on the same treatment measures. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in the PHIRST study cohort of 340 subjects (264 females, 76 males). A univariate analysis was used to assess the effect of sex on change in 6MWD and TCW. Multivariate linear regression and Cox proportional hazards models were built for 6MWD and TCW, respectively. Women were subdivided by age as a surrogate for menopausal status. The linear trend test and the log-rank test were performed on change in 6MWD and TCW by age. For tadalafil-treated patients, a significant difference in change in 6MWD by sex (mean: 48.6 m for males vs. 34.7 m for females; P = 0.01) was found, buy tadalafil but it was not significant in multivariate analysis (P = 0.08). There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement. A significant sex- or age-dependent effect on TCW was not present. In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a paucity of literature investigating the effect of menopause on response to PAH treatment.

Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH. Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point. In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor. Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in 6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status. Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required.